Johnson & Johnson forecasts $2.5 bn in Covid-19 vaccine sales this year

(Reuters) – Johnson & Johnson on Wednesday forecast just $2.5 billion in 2021 sales of its COVID-19 vaccine, which has fallen way behind rival shots from Pfizer and Moderna as the company deals with vaccine production issues and safety concerns.